Patient compliance with treatment regimens is a well established challenge in chronic disease, with diabetes, asthma and hypertension having the worse patient compliance track records. One of the largest Pharmacy Benefit Managers, Express Scripts, will be more actively monitoring patients for compliance and contacting if they fall behind in their treatment. http://www.stltoday.com/business/local/express-scripts-to-spot-pill-skippers-with-new-program/article_8b90b844-87ea-11e1-ab90-0019bb30f31a.html What is interesting …
Read More
Is there a novel path for Obesity development? – Hope springs eternal with the FDA
Limited use. Targeted populations. Smaller trial sizes. Faster approvals. These are the traits of cancer drug development, not obesity, correct? The FDA’s top drug administrator Janet Woodcock, made comments in support of legislation that would potentially include obesity in a regulatory world typically reserved for smaller populations. Article text below. The cynical FDA …
Read More
Good Lancet Article on Qnexa
Metabolic Markets commented a few months about about the structure of the risk mitigation approach from both a label and distribution control standpoint for Qnexa and what approach would would give the FDA confidence (code for: “political cover”) to approve. An article in the LANCET recently dove into the advisory panel vote. In …
Read More
Post-Qnexa Panel, is the FDA bamboo or will they finally break in obesity?
The surprising 20-2 advisory panel vote in favor of Qnexa’s approval has uncorked media coverage of the obesity issue. Countless news stories and editorials have been published in the last week. The overwhelming vote may have forced the FDA’s hand to approve Qnexa, breaking under the mounting pressures in recent years to approve an obesity …
Read More
Breaking News- FDA advisory panel votes in favor of Vivus’ Qnexa
By a surprisingly overwhelming vote, 20-2 in favor. Reporting by http://www.thestreet.com/story/11427956/1/vivus-fda-panel-live-blog.html But my good friends and neighbors, will the FDA accept the panel’s recommendation? Is Qnexa really the drug that the Agency wants to have as the first obesity agent in many years? The one with the ever so slight risk of cleft-palate? I’m just …
Read More
What an amazing? time we live in – “watching” the Qnexa advisory panel right now
I”m following a live blog from the street.com on the Qnexa advisory panel. There are no secrets. http://www.thestreet.com/story/11427956/1/vivus-fda-panel-live-blog.html cool stuff.
Bydureon: if you build it, will they come? We will know soon
Amylin and Alkermes announced last week that Bydureon was now available in U.S pharmacies. (On a side note, I love any launch press release with “first and only” in the headline. I’m sure that was mentioned in every market research session as “important,” it happens every new launch, I love looking for it, but …
Read More
The oft-debated role of the Employer in the obesity/diabetes discussion continues…….
It sounds so simple. Employers, particularly large ones should care (code for “invest”) in their employees wellness and reduce multiple healthcare risks, and potentially reduce employee absenteeism. So simple. so straightforward. Metabolic Markets has an ongoing employer project and it has been fascinating to see only a segment of employers truly embrace this concept and …
Read More
Bydureon vs. Victoza? Super Bowl? M2 makes our prediction
Metabolic Markets has developed a GLP-1 market briefing for our clients education and discussion. Entitled: “The U.S. GLP-1 Market Brief: Yesterday, Today, and Tomorrow” The brief slide deck reviews the history of Byetta, shares our clinical and commercial experience, Victoza introduction, and short term considerations to watch as the market unfolds with the pending Bydureon …
Read More
The Franchise – Januvia / the 800 lb gorilla
Merck release 2011 results yesterday, and to no surprise, the Januvia machine, 800 lbs gorilla, or as I like to call it “The Franchise,” continues to perform. The Franchise posted $3.324 billion in 2011 global sales, up from $2.38 billion in 2010. Let’s contrast this to the later entrants in the DPP-IV class Galvus: $677 …
Read More